These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35623961)

  • 1. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
    Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Basset-Seguin N; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Forsea AM; Grob JJ; Hoeller C; Kaufmann R; Kelleners-Smeets N; Lallas A; Lebbé C; Lytvynenko B; Malvehy J; Moreno-Ramirez D; Nathan P; Pellacani G; Saiag P; Stratigos AJ; Van Akkooi ACJ; Vieira R; Zalaudek I; Lorigan P;
    Eur J Cancer; 2022 Jul; 170():256-284. PubMed ID: 35623961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
    Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Grob JJ; Höller C; Kaufmann R; Lallas A; Lebbé C; Malvehy J; Middleton M; Moreno-Ramirez D; Pellacani G; Saiag P; Stratigos AJ; Vieira R; Zalaudek I; Eggermont AMM;
    Eur J Cancer; 2020 Feb; 126():159-177. PubMed ID: 31866016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.
    Garbe C; Peris K; Hauschild A; Saiag P; Middleton M; Bastholt L; Grob JJ; Malvehy J; Newton-Bishop J; Stratigos AJ; Pehamberger H; Eggermont AM; ; ;
    Eur J Cancer; 2016 Aug; 63():201-17. PubMed ID: 27367293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.
    Garbe C; Peris K; Hauschild A; Saiag P; Middleton M; Spatz A; Grob JJ; Malvehy J; Newton-Bishop J; Stratigos A; Pehamberger H; Eggermont AM; ; ;
    Eur J Cancer; 2012 Oct; 48(15):2375-90. PubMed ID: 22981501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.
    Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Grob JJ; Höller C; Kaufmann R; Lallas A; Lebbé C; Malvehy J; Middleton M; Moreno-Ramirez D; Pellacani G; Saiag P; Stratigos AJ; Vieira R; Zalaudek I; Eggermont AMM;
    Eur J Cancer; 2020 Feb; 126():141-158. PubMed ID: 31928887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.
    Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Basset-Seguin N; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Forsea AM; Grob JJ; Höller C; Kaufmann R; Kelleners-Smeets N; Lallas A; Lebbé C; Lytvynenko B; Malvehy J; Moreno-Ramirez D; Nathan P; Pellacani G; Saiag P; Stratigos AJ; Van Akkooi ACJ; Vieira R; Zalaudek I; Lorigan P;
    Eur J Cancer; 2022 Jul; 170():236-255. PubMed ID: 35570085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which adjuvant treatment for patients with BRAF
    Funck-Brentano E; Malissen N; Roger A; Lebbé C; Deilhes F; Frénard C; Dréno B; Meyer N; Grob JJ; Tétu P; Saiag P
    Ann Dermatol Venereol; 2021 Sep; 148(3):145-155. PubMed ID: 33579557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.
    Garbe C; Peris K; Hauschild A; Saiag P; Middleton M; Spatz A; Grob JJ; Malvehy J; Newton-Bishop J; Stratigos A; Pehamberger H; Eggermont A
    Eur J Cancer; 2010 Jan; 46(2):270-83. PubMed ID: 19959353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
    Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
    Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
    Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.
    Stratigos A; Garbe C; Lebbe C; Malvehy J; del Marmol V; Pehamberger H; Peris K; Becker JC; Zalaudek I; Saiag P; Middleton MR; Bastholt L; Testori A; Grob JJ; ; ;
    Eur J Cancer; 2015 Sep; 51(14):1989-2007. PubMed ID: 26219687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
    Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
    Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
    Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV
    J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
    Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.